Form 4: Cytokinetics Director John T. Henderson Reports Acquisition of Common Stock

Director John T. Henderson reports acquiring 388 shares of Cytokinetics Inc. common stock in lieu of a cash retainer payment.

Summary

• On July 1, 2024, John T. Henderson, a director of Cytokinetics Inc., acquired 388 shares of common stock.
• The acquisition was made in lieu of a cash retainer payment.
• Following the transaction, Henderson directly owns 38,058 shares of Cytokinetics Inc. common stock.
• Henderson also indirectly owns 83 shares through his spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director. While insider buying can be seen as positive, this is a small amount in lieu of a retainer.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, but it provides transparency into the actions of a company director.

Key Dates